Azenta, Inc. (AZTA): Modelo de negócios Canvas [Jan-2025 Atualizado]

No cenário dinâmico da inovação científica, a Azenta, Inc. (AZTA) surge como uma potência de precisão tecnológica, preenchendo estrategicamente os complexos mundos das ciências da vida e as tecnologias de semicondutores. Com um modelo de negócios intrincado que tece juntos pesquisas de ponta, fabricação avançada e soluções especializadas, a Azenta transforma os desafios científicos em oportunidades inovadoras em domínios farmacêuticos, biotecnológicos e de pesquisa. Sua abordagem única combina sofisticados sistemas de armazenamento criogênico, equipamentos de alta precisão e um profundo compromisso com o avanço tecnológico que os diferencia em um mercado global em rápida evolução.

Azenta, Inc. (AZTA) - Modelo de negócios: Parcerias -chave

Colaborações estratégicas com instituições de pesquisa em ciências da vida

A Azenta, Inc. mantém parcerias estratégicas com as seguintes instituições de pesquisa:

Instituição de pesquisa	Foco em parceria	Ano estabelecido
Escola de Medicina de Harvard	Tecnologias avançadas de bioprocessamento	2022
MIT Whitehead Institute	Soluções de gerenciamento de amostras genômicas	2021

Parcerias com empresas farmacêuticas e de biotecnologia

As principais parcerias farmacêuticas e de biotecnologia incluem:

• Pfizer Inc. - Gerenciamento de amostras colaborativas e logística
• Moderna Therapeutics - Soluções biorrepositivas avançadas
• Bristol Myers Squibb - Precision Cold Chain Technologies

Relacionamentos de fornecedores com materiais avançados e fabricantes de equipamentos

Relacionamentos críticos de fornecedores abrangem:

Fornecedor	Categoria de fornecimento	Valor anual do contrato
Thermo Fisher Scientific	Equipamento de laboratório	US $ 12,5 milhões
Corning incorporado	Materiais avançados	US $ 8,3 milhões

Alianças com centros de pesquisa acadêmica e universidades

Parcerias de pesquisa acadêmica significativas:

• Stanford University - Colaboração de pesquisa de bioengenharia
• Universidade Johns Hopkins - Gerenciamento de amostras de medicina de precisão
• Universidade da Califórnia, São Francisco - Desenvolvimento de Tecnologia Genômica

Azenta, Inc. (AZTA) - Modelo de negócios: Atividades -chave

Projetar e fabricar ciências da vida e equipamentos semicondutores

No ano fiscal de 2023, a Azenta registrou receita de vendas de equipamentos de US $ 340,7 milhões, com foco em processos especializados de fabricação.

Categoria de equipamento	Volume anual de produção	Locais de fabricação
Equipamento de ciências da vida	1.200 unidades	Woburn, MA e Xangai, China
Equipamento semicondutor	850 unidades	Billerica, MA

Soluções de gerenciamento de amostras e armazenamento criogênicas

A Azenta opera 8 instalações biorrepositivas globais com uma capacidade total de armazenamento de mais de 500 milhões de amostras biológicas.

• Sistemas de armazenamento criogênico implantados em 42 países
• Receita anual de serviços de gerenciamento de amostra: US $ 127,5 milhões
• Mais de 3.500 instituições de pesquisa e empresas farmacêuticas serviram

Pesquisa e desenvolvimento de tecnologias avançadas

O investimento em P&D para o ano fiscal de 2023 foi de US $ 62,4 milhões, representando 11,6% da receita total da empresa.

Área de foco em P&D	Aplicações de patentes	Projetos de pesquisa ativa
Tecnologias criogênicas	23	12
Processamento de semicondutores	18	9

Processos de engenharia e fabricação de precisão

Tolerância à precisão da fabricação: ± 0,001 mm entre componentes críticos do equipamento.

• Instalações de fabricação certificadas ISO 9001: 2015
• Tempo médio de ciclo de fabricação: 6-8 semanas
• Taxa de rejeição de controle de qualidade: menos de 0,5%

Serviços globais de vendas e suporte ao cliente

Cobertura global de vendas em 6 continentes, com 247 vendas e pessoal de suporte dedicados.

Região	Representantes de vendas	Horário anual de suporte ao cliente
América do Norte	98	42,500
Europa	67	29,300
Ásia-Pacífico	82	36,800

Azenta, Inc. (AZTA) - Modelo de negócios: Recursos -chave

Engenharia especializada e especialização técnica

Azenta, Inc. mantém um força de trabalho técnica altamente especializada Com a seguinte composição:

Categoria de funcionários	Número de funcionários
Pessoal total de P&D	387
Cientistas do nível de doutorado	129
Especialistas em engenharia	258

Instalações de fabricação avançadas

A Azenta opera várias instalações de fabricação com as seguintes especificações:

• Locais de fabricação total: 6
• Regiões de fabricação primária: Estados Unidos, China, Cingapura
• MAGAGEM SQUETRO DE FABRICAÇÃO TOTAL: 275.000 pés quadrados

Tecnologias proprietárias

Categoria de tecnologia	Número de tecnologias proprietárias
Tecnologias de armazenamento criogênico	17
Tecnologias de equipamentos semicondutores	23
Tecnologias de automação de ciências da vida	12

Portfólio de propriedade intelectual

Os ativos de propriedade intelectual da Azenta incluem:

• Total de patentes ativas: 142
• Aplicações de patentes pendentes: 38
• Famílias de patentes: 56

Força de trabalho qualificada

Composição da força de trabalho	Número de funcionários
Total de funcionários	1,643
Titulares de graduação avançados	412
Especialistas técnicos	987

Azenta, Inc. (AZTA) - Modelo de negócios: proposições de valor

Equipamentos científicos de alta precisão para pesquisa e aplicações clínicas

Azenta oferece equipamentos científicos com as seguintes especificações:

Tipo de equipamento	Nível de precisão	Segmento de mercado
Sistemas de armazenamento criogênico	± 0,1 ° C precisão	Biororrepositório
Plataformas de gerenciamento de amostra	99,9% de confiabilidade de rastreamento	Laboratórios de pesquisa
Ferramentas de fabricação de semicondutores	Precisão no nível do nanômetro	Fabricação de alta tecnologia

Soluções inovadoras de gerenciamento de amostras para ciências da vida

As soluções de gerenciamento de amostras de Azenta incluem:

• Sistemas de rastreamento de amostra automatizados
• Infraestrutura de armazenamento criogênico
• Plataformas de gerenciamento de amostra de ponta a ponta

Tecnologias avançadas de fabricação de semicondutores

Ofertas de tecnologia de semicondutores:

Tecnologia	Métrica de desempenho	Aplicação de mercado
Sistemas de manuseio de bolacha	Compatibilidade de wafer de 300 mm	Produção de semicondutores
Ferramentas de alinhamento de precisão	Posicionamento de sub-micron	Fabricação avançada de chips

Sistemas de armazenamento criogênico confiáveis ​​e escaláveis

Recursos de armazenamento criogênico:

• Capacidade de armazenamento: até 10 milhões de amostras biológicas
• Faixa de temperatura: -190 ° C a +37 ° C
• Taxa de preservação da integridade da amostra: 99,99%

Soluções tecnológicas de ponta para desafios científicos complexos

Métricas de solução tecnológica:

Categoria de solução	Capacidade tecnológica	Impacto no mercado
Automação de ciências da vida	Gerenciamento de amostras orientado a IA	Melhoria da eficiência da pesquisa
Processamento de semicondutores	Manuseio avançado de material	Manufatura de aprimoramento de precisão

Azenta, Inc. (AZTA) - Modelo de negócios: relacionamentos com o cliente

Suporte de vendas diretas e consulta técnica

A Azenta fornece suporte direto de vendas por meio de uma equipe dedicada de 87 profissionais de vendas a partir do quarto trimestre 2023. A empresa registrou US $ 524,7 milhões em receita total para o ano fiscal de 2023, com serviços de consulta técnica especializados integrados em vários segmentos de negócios.

Métrica de suporte ao cliente	2023 dados
Total de representantes de vendas	87
Tempo médio de interação do cliente	2,3 horas por consulta
Tempo de resposta de suporte técnico	4,1 horas

Programas de treinamento e educação em andamento

A Azenta oferece programas de treinamento abrangentes em ciências da vida e mercados de equipamentos semicondutores.

• Sessões anuais de treinamento: 42 workshops
• Módulos de treinamento on -line: 26 cursos digitais
• Participantes de treinamento certificado: 1.284 em 2023

Serviço personalizado para clientes de pesquisa e industrial

A empresa atende 1.356 instituições de pesquisa e clientes industriais com Pacotes de solução personalizados.

Segmento de cliente	Número de clientes	Nível de personalização
Instituições de pesquisa	782	Alto
Clientes industriais	574	Médio a alto

Abordagem de parceria de longo prazo

A Azenta mantém uma taxa média de retenção de clientes de 89,6% em seus segmentos de negócios, com 73 clientes tendo parcerias superiores a 10 anos.

Serviços de Suporte Técnico e Manutenção Responsivos

A infraestrutura de suporte técnico inclui 132 engenheiros de suporte dedicados com cobertura global.

• Centros de Suporte Global: 7 Locais
• Disponibilidade de suporte técnico 24/7
• Tempo de atividade média do equipamento: 97,3%

Métrica de suporte	Desempenho
Engenheiros de suporte total	132
Centros de Suporte Global	7
Interações de suporte anual	4,672

Azenta, Inc. (Azta) - Modelo de Negócios: Canais

Equipe de vendas diretas

A partir de 2024, a Azenta mantém uma força de vendas direta dedicada de aproximadamente 215 profissionais de vendas nos mercados globais. A equipe de vendas se concentra em ciências da vida, semicondutores e indústrias de materiais avançados.

Região de vendas	Número de representantes de vendas
América do Norte	95
Europa	65
Ásia-Pacífico	55

Plataformas online de comércio eletrônico

A Azenta opera vários canais de vendas digitais com um volume anual de transações on -line de US $ 87,3 milhões em 2023.

• Site da empresa (portal de vendas direta)
• Mercados de equipamentos científicos especializados
• Plataformas de compras digitais

Conferências científicas e feiras

A Azenta participa de 42 conferências científicas e tecnológicas internacionais anualmente, com um gasto estimado em marketing de US $ 2,4 milhões.

Redes de distribuidores

A empresa mantém parcerias com 87 distribuidores globais de equipamentos científicos em 23 países.

Região	Número de distribuidores
América do Norte	28
Europa	32
Ásia-Pacífico	27

Canais de marketing digital e comunicação técnica

Azenta aproveita várias plataformas de comunicação digital com as seguintes métricas de engajamento:

• Seguidores do LinkedIn: 45.670
• Seguidores do Twitter: 22.340
• Participantes do webinar técnico (2023): 3.850
• Orçamento anual de marketing digital: US $ 1,7 milhão

Azenta, Inc. (AZTA) - Modelo de negócios: segmentos de clientes

Organizações de pesquisa farmacêutica

A Azenta serve organizações de pesquisa farmacêutica com soluções críticas de ciências da vida. A partir de 2023, o mercado global de pesquisa farmacêutica foi avaliada em US $ 179,4 bilhões.

Tipo de cliente	Tamanho estimado do mercado	Taxa de penetração
20 principais empresas farmacêuticas	US $ 98,6 bilhões	54.9%
Organizações de pesquisa farmacêutica de tamanho médio	US $ 52,3 bilhões	29.1%

Empresas de biotecnologia

As empresas de biotecnologia representam um segmento significativo de clientes para as tecnologias de ciências da vida da Azenta.

• Tamanho do mercado global de biotecnologia em 2023: US $ 627,2 bilhões
• Número de empresas ativas de biotecnologia em todo o mundo: 8.442
• Gastos estimados em P&D: US $ 186,3 bilhões anualmente

Instituições de pesquisa acadêmica e governamental

A Azenta fornece equipamentos e serviços especializados para instituições de pesquisa.

Tipo de instituição	Número de clientes em potencial	Orçamento de pesquisa anual
As 100 melhores universidades de pesquisa	100	US $ 68,4 bilhões
Laboratórios de Pesquisa Governamental	237	US $ 45,7 bilhões

Empresas de fabricação de semicondutores

A fabricação de semicondutores representa um segmento crescente de clientes para a Azenta.

• Tamanho do mercado global de semicondutores em 2023: US $ 573,4 bilhões
• Número de fabricantes ativos de semicondutores: 332
• Gastos estimados para equipamentos de capital: US $ 89,6 bilhões

Laboratórios de Saúde e Clínicos

Os laboratórios clínicos representam um segmento crítico de clientes para as soluções de diagnóstico da Azenta.

Tipo de laboratório	Número total	Volume de teste anual
Laboratórios de Diagnóstico Clínico	6,773	8,2 bilhões de testes anualmente
Laboratórios hospitalares	5,534	4,7 bilhões de testes anualmente

Azenta, Inc. (AZTA) - Modelo de negócios: estrutura de custos

Investimentos de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Azenta, Inc. registrou despesas de P&D de US $ 91,4 milhões, representando 13,4% da receita total.

Ano fiscal	Despesas de P&D	Porcentagem de receita
2023	US $ 91,4 milhões	13.4%
2022	US $ 83,2 milhões	12.9%

Despesas de fabricação e produção

Os custos totais de fabricação para a Azenta em 2023 foram de US $ 237,6 milhões, com o colapso chave da seguinte maneira:

• Custos de mão -de -obra direta: US $ 68,3 milhões
• Despesas de matéria -prima: US $ 112,5 milhões
• Manufatura de sobrecarga: US $ 56,8 milhões

Operações globais de vendas e marketing

As despesas de vendas e marketing para Azenta no ano fiscal de 2023 totalizaram US $ 129,7 milhões.

Região geográfica	Gastos com marketing
América do Norte	US $ 62,4 milhões
Europa	US $ 37,2 milhões
Ásia-Pacífico	US $ 30,1 milhões

Manutenção de infraestrutura de tecnologia

Os custos de manutenção de tecnologia e infraestrutura para 2023 foram de US $ 45,6 milhões, incluindo:

• Atualizações de sistemas de TI: US $ 22,3 milhões
• Investimentos de segurança cibernética: US $ 12,5 milhões
• Infraestrutura em nuvem: US $ 10,8 milhões

Aquisição e retenção de talentos

Recursos humanos e despesas relacionadas a talentos em 2023 totalizaram US $ 96,2 milhões.

Categoria de despesa	Quantia
Salários e salários	US $ 76,5 milhões
Benefícios dos funcionários	US $ 15,3 milhões
Recrutamento e treinamento	US $ 4,4 milhões

Azenta, Inc. (AZTA) - Modelo de negócios: fluxos de receita

Vendas de equipamentos no setor de ciências da vida

Para o ano fiscal de 2023, a Azenta relatou vendas de equipamentos de ciências da vida de US $ 281,4 milhões.

Categoria de produto	Receita ($ m)	Porcentagem de total
Sistemas de gerenciamento de amostra automatizados	156.7	55.7%
Equipamento de pesquisa genômica	124.6	44.3%

Soluções de equipamentos semicondutores

As soluções de equipamentos semicondutores geraram US $ 202,3 milhões em receita para o ano fiscal de 2023.

Segmento de semicondutores	Receita ($ m)
Equipamento avançado de embalagem	112.5
Soluções de teste de semicondutores	89.8

Receita do sistema de armazenamento de amostra criogênica

Os sistemas de armazenamento criogênico contribuíram com US $ 97,6 milhões para a receita total da Azenta em 2023.

• Soluções de armazenamento biorrepositório: US $ 62,3 milhões
• Sistemas criogênicos institucionais de pesquisa: US $ 35,3 milhões

Contratos de manutenção e serviço contínuos

Os contratos de serviço e manutenção geraram US $ 73,8 milhões em receita recorrente para o ano fiscal de 2023.

Tipo de serviço	Valor anual do contrato ($ m)
Manutenção do equipamento	48.5
Contratos de suporte técnico	25.3

Serviços de licenciamento e consultoria de tecnologia

Os serviços de licenciamento e consultoria de tecnologia representaram US $ 41,2 milhões na receita de 2023.

• Licenciamento de propriedade intelectual: US $ 24,7 milhões
• Serviços de consultoria: US $ 16,5 milhões

Receita anual total (2023): US $ 696,3 milhões

Azenta, Inc. (AZTA) - Canvas Business Model: Value Propositions

You're looking at the core reasons why pharmaceutical and biotech clients choose Azenta, Inc. for their critical research infrastructure. It's about de-risking their most valuable assets-their biological samples-and speeding up their R&D timelines. The numbers show where the business is focused.

Flawless sample integrity via automated cold-chain management.

This value proposition is anchored in the Sample Management Solutions (SMS) segment, which provides the physical and logistical backbone for sample preservation. The focus here is on reliability at scale, which is essential for multi-year clinical trials and biobanking efforts. The company's ability to maintain viability across ultra-low temperatures is non-negotiable for customers.

The financial contribution from this area for the full fiscal year 2025 was substantial:

Metric	Amount/Value
Full Year Fiscal 2025 SMS Revenue	$325 million
Q3 Fiscal 2025 SMS Revenue	$78 million
Q4 Fiscal 2025 SMS Revenue	$86 million

The Q3 2025 revenue for SMS was down 4% year-over-year, but Q4 saw a rebound with 2% reported growth, showing the lumpy nature of capital equipment sales like Automated Stores.

Accelerating drug discovery with high-throughput multiomics services.

The Multiomics segment is the growth engine, providing the analytical horsepower needed to turn stored samples into actionable data. This includes Next Generation Sequencing (NGS), which has been a consistent performer.

• NGS volume growth was at double-digit rates in Q2 2025.
• NGS pricing showed stabilization for the 4th consecutive quarter as of Q2 2025.
• Q3 Fiscal 2025 Multiomics Revenue was $66 million, up 4% year-over-year.
• Full Year Fiscal 2025 Multiomics Revenue was $269 million, up 6% year-over-year.

This segment's performance is key to the overall organic growth trajectory. For the full year 2025, Azenta, Inc.'s total organic revenue grew 3%.

End-to-end sample lifecycle management for complex therapies.

This value is the sum of both segments, supported by a strong balance sheet to ensure continuity of service, which is critical when managing samples for advanced cell and gene therapies. The company ended fiscal year 2025 with a total balance of cash, cash equivalents, and marketable securities of $546 million.

The overall financial results for the full fiscal year 2025 reflect this integrated approach:

• Full Year Fiscal 2025 Total Revenue: $594 million.
• Full Year Fiscal 2025 Adjusted EBITDA Margin: 11.2%, an improvement of 310 basis points year-over-year.
• Full Year Fiscal 2025 Non-GAAP Diluted EPS: $0.51.

The margin expansion, up 310 basis points for the year, shows the value of operational efficiencies being realized across the entire lifecycle management process.

Reduced time and cost to lead candidates in gene therapy.

Azenta, Inc. directly addresses the timeline and safety concerns in gene therapy development through strategic integrations. For instance, a partnership launched in May 2025 integrates their sequencing capabilities with Form Bio's computational solutions to provide AAV Genome Integrity Characterization using their LAAVA software.

This collaboration is designed to streamline lead candidate selection by providing data-driven insights into AAV capsid contents, aiming to enhance therapeutic safety and manufacturability, which directly translates to reduced development timelines and costs for gene therapy developers.

Enterprise-wide sample intelligence software and informatics.

The informatics layer, which includes software like Freezer Pro and Limfinity, transforms raw sample data into intelligence. This software underpins the reliability of the entire cold-chain service, ensuring data integrity matches sample integrity. While specific revenue for informatics is bundled, the focus on operational improvements across the board supports this value.

The company's commitment to operational excellence is evident in its profitability metrics, which are a direct result of better system utilization and cost execution:

Metric (Continuing Operations)	Q3 Fiscal 2025	Q4 Fiscal 2025
Adjusted EBITDA Margin	12.3%	13%
Non-GAAP Diluted EPS	$0.19	$0.21

Finance: draft 13-week cash view by Friday.

Azenta, Inc. (AZTA) - Canvas Business Model: Customer Relationships

You're looking at how Azenta, Inc. (AZTA) structures its interactions across its diverse product and service offerings as of late 2025. The approach is definitely segmented based on the value and complexity of the offering.

For high-value systems, like the Automated Stores and Cryogenic Systems, Azenta, Inc. relies on a dedicated direct sales force. This team manages the complex sales cycle for these capital equipment and the associated storage services. Management noted in their Q4 2025 update that they took decisive steps to reshape the commercial organization, including an expanded field presence, to sharpen go-to-market targeting for fiscal 2025.

The Sample Repository Services (SRS), a key part of the Sample Management Solutions (SMS) segment, necessitates consultative, long-term relationships. These services are foundational to the trust required for long-term sample custody. The revenue performance of this segment, which includes SRS, shows its scale:

Period Ended	Sample Management Solutions Revenue (Millions USD)	Year-over-Year Change
March 31, 2025 (Q2 FY25)	$80	8% increase
June 30, 2025 (Q3 FY25)	$78	4% decrease
September 30, 2025 (Q4 FY25)	$86	2% increase

For consumables and standard services, the relationship leans toward self-service and e-commerce channels. These are the more transactional elements of the business. The growth in these areas, specifically for Consumables and Instruments, was noted as a meaningful contributor to the Q4 2025 results.

Support for the installed base of systems is managed through technical support and service contracts. This ensures uptime and continued use of their hardware and software platforms, such as Freezer Pro and Limfinity. The SMS segment also reports revenue from Product Services, which falls under this relationship type.

Azenta, Inc. maintains definitely collaborative relationships with top pharma, as they provide services to the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. This focus is critical, as the company's overall fiscal year 2025 revenue was $593.8 million, with 39% of that revenue generated outside the United States in fiscal year 2025, showing a growing international footprint with these key customers.

• The company ended the fiscal year 2025 with $546 million in cash, cash equivalents, and marketable securities.
• The debt-to-equity ratio stood at a low 0.03.
• The overall business achieved an Adjusted EBITDA Margin of 11.2% for the full fiscal year 2025.

Finance: review the Q1 2026 sales pipeline against the 3% to 5% organic growth guidance for the full year 2026 by end of January.

Azenta, Inc. (AZTA) - Canvas Business Model: Channels

You're looking at how Azenta, Inc. (AZTA) gets its Sample Management Solutions and Multiomics services into the hands of pharmaceutical and biotech clients as of late 2025. The channels reflect a hybrid approach, mixing direct engagement for high-value services with broader distribution for core products.

The direct sales force targets the two core continuing operations segments. For the third quarter of fiscal year 2025, the Sample Management Solutions segment generated $78 million in revenue, while the Multiomics segment brought in $66 million. The direct team is essential for selling complex, automated cold-chain infrastructure and high-throughput genomic services.

For core products, Azenta, Inc. relies on a trusted network of third-party distributors globally. While the exact number of partners isn't public, this channel helps extend reach for products like consumables and instruments, which contributed to the Sample Management Solutions revenue decline of 4% year-over-year in Q3 fiscal 2025.

The company-owned biorepository and service centers form a critical physical channel, ensuring sample integrity and local access. As of the June 30, 2025, balance sheet date, Azenta, Inc. maintained a cash and liquidity balance of $565 million, supporting this global footprint. The new biorepository in Greater Boston, for instance, is a 40,000 square foot facility.

Here is a look at the known physical channel locations supporting their operations:

Region	City/Site	Type of Facility Mentioned
North America	Burlington, MA	Corporate Headquarters
North America	Indianapolis, IN	Flagship Biorepository
North America	Waltham, MA	Multiomics Location
North America	Research Triangle Park, NC	Laboratory/Facility
North America	Seattle, WA	Laboratory/Facility
Europe	Leipzig, Germany	Laboratory/Facility
Europe	Oxford, United Kingdom	Laboratory/Facility

Investor relations and webcasts serve as the direct channel to the financial community. Management is focused on margin expansion, projecting 300 basis points of Adjusted EBITDA margin expansion for the full fiscal year 2025.

• Azenta Life Sciences Investor Day was scheduled for Wednesday, December 10, 2025, with the webcast presentation starting at 1:00 PM ET.
• The Q4 and Full Year Fiscal 2025 Earnings Conference Call and Webcast was scheduled for Friday, November 21, 2025, at 8:30 AM ET.
• The company's Market Capitalization as of November 21, 2025, was reported at $1.38 billion.

Digital platforms are key for the Multiomics business, which includes the GENEWIZ brand. GENEWIZ from Azenta Life Sciences provides services like Next Generation Sequencing and Gene Synthesis. While the platform facilitates ordering and payment, specific digital ordering volume or user statistics for fiscal 2025 aren't reported.

The digital channel is reinforced through strategic integrations, such as the partnership announced in May 2025 with Form Bio to enhance AAV gene therapy development through an integrated sequencing and data analysis solution. The overall Fiscal 2025 reported revenue was $593.82 million, with a reported loss of -$59.50 million.

Finance: draft 13-week cash view by Friday.

Azenta, Inc. (AZTA) - Canvas Business Model: Customer Segments

You're looking at the customer base for Azenta, Inc. as of late 2025, which is entirely focused on life sciences, having completed the strategic pivot away from semiconductor automation. The company's total revenue for the fiscal year ending September 30, 2025, reached $593.82M, with an organic growth rate of 3% for that full year. This revenue supports a global customer base, as 39% of total revenue was generated outside the United States in fiscal year 2025.

Azenta, Inc. serves its customers through two primary reporting segments: Sample Management Solutions (SMS) and Multiomics. These segments map directly to the essential needs of drug developers, researchers, and healthcare providers.

The Sample Management Solutions segment is the backbone for customers needing secure, long-term sample integrity. For instance, in the third quarter of fiscal year 2025, this segment generated $78 million in revenue, driven by services like Sample Repository Solutions and Core Products. In the fourth quarter, SMS revenue was $86 million, showing strength in areas like Clinical Biostores and Sample Storage, even with softness in Cryogenic Stores due to customer capital expenditure delays.

The Multiomics segment is the growth engine, focused on genomic services essential for modern therapy development. In the third quarter of fiscal year 2025, Multiomics revenue was $66 million, up 4% year-over-year, primarily fueled by Next Generation Sequencing. This segment directly supports advanced cell and gene therapy developers and large biotech firms needing high-throughput analysis.

Here's a quick look at the segment revenue performance from the third quarter of fiscal 2025, which gives you a clear picture of where the business was at that point:

Segment	Revenue (Q3 FY2025, in millions USD)	Year-over-Year Organic Growth (Q3 FY2025)
Sample Management Solutions	$78	-6%
Multiomics	$66	3%
Total Revenue (Continuing Operations)	$144	-2%

The customer segments are served by specific offerings within these structures. You're looking at a customer base that relies on Azenta, Inc. for mission-critical infrastructure and analysis.

• Top pharmaceutical and biotechnology companies use both segments for drug development pipelines.
• Academic and government research institutions are key users of Multiomics for discovery research.
• Clinical research organizations (CROs) and clinical trial sponsors rely heavily on Sample Management Solutions for trial material integrity.
• Advanced cell and gene therapy developers require Multiomics for sequencing and SMS for ultra-low temperature storage.
• Healthcare institutions and biobanks globally utilize Sample Repository Services and Clinical Biostores.

For the full year 2025, the company reported a strong cash position, ending the year with $283.5 million in cash, cash equivalents, and restricted cash, plus $262.7 million in marketable securities, ensuring they can continue to support these long-term customer relationships.

The Multiomics segment saw particular momentum, with organic revenue growing 10% year-over-year in the fourth quarter of fiscal 2025, driven by Next Generation Sequencing and Gene Synthesis, which are services directly tied to the most innovative drug development efforts.

Finance: draft 13-week cash view by Friday.

Azenta, Inc. (AZTA) - Canvas Business Model: Cost Structure

You're looking at the core expenses that drive Azenta, Inc.'s operations as of late 2025, focusing on the continuing businesses after the planned divestiture of B Medical Systems. The cost structure reflects a pivot toward high-tech services in Sample Management Solutions (SMS) and Multiomics.

Cost of revenue (COGS) for consumables and instruments is a primary driver. While specific 2025 COGS for consumables and instruments isn't fully itemized separately from the continuing operations' gross margin, we can infer the cost base from recent performance. For the third quarter of fiscal 2025, continuing operations generated revenue of $144 million, with an Adjusted Gross Margin of 48.5%. This implies an Adjusted Cost of Revenue of approximately $74.16 million for that quarter, which covers the direct costs associated with providing sample management products, consumables, and multiomics sequencing services. For context, the Total Cost of Revenue for the full fiscal year 2024 was $393 million on $656 million in total revenue, before the B Medical segment was classified as discontinued. The focus on higher-margin services within SMS and Multiomics is intended to improve this ratio.

Significant R&D investment for automation and multiomics expansion is managed with discipline. In the third quarter of fiscal 2025, Research and Development costs were lower year-over-year, contributing to a 6% decrease in total GAAP Operating Expenses compared to the prior year period. On a Non-GAAP basis for Q3 2025, Adjusted Operating Expense was $62 million, down 4% year-over-year, driven in part by lower R&D costs. This suggests a near-term focus on operational efficiency while maintaining necessary investment in automation for their Sample Management Solutions, such as automated stores and cryogenic systems, and expansion in Multiomics capabilities like Next Generation Sequencing.

Selling, General, and Administrative (SG&A) expenses for global sales are being tightly controlled as part of the transformation program. For Q3 2025, lower Selling, General, and Administrative expenses were a key factor in reducing the Adjusted Operating Expense to $62 million, down from $69 million in Q2 2025. This reduction in SG&A helped drive the Adjusted Operating Margin for Q3 2025 to 5.5% for continuing operations. The global sales force supports the Sample Management Solutions and Multiomics segments across North America, Europe, and Asia.

Operating costs for global biorepository and cold-chain infrastructure are embedded within COGS and operating expenses, reflecting the complexity of maintaining reliable cold-chain custody. The Sample Management Solutions segment revenue, which includes these services, was $78 million in Q3 2025. The company's commitment to this infrastructure is a fixed cost component that underpins the value proposition of sample integrity. Capital expenditures for the full fiscal year 2024 were approximately $38 million, indicating ongoing investment in these physical assets.

Restructuring and portfolio simplification costs (e.g., B Medical sale) have been a notable, though temporary, cost factor. The intention to sell the B Medical Systems segment was announced in fiscal Q1 2025, leading to its classification as a discontinued operation. In Q2 2025, the company noted increased restructuring and transformation charges. However, by Q3 2025, GAAP Operating Expenses reflected lower restructuring charges year-over-year. These charges are adjustments not representative of normal operations, but they impacted the GAAP results, contributing to the total diluted EPS loss of ($0.88) in Q2 2025, which included ($0.49) from discontinued operations.

Here's a quick look at the latest reported operational expense snapshot for continuing operations (Q3 2025):

Metric (Continuing Operations)	Q3 2025 (USD Millions)	Change vs. Q2 2025	Change vs. Q3 2024
Revenue	144	0%	0%
Adjusted Operating Expense	62	Down 10.1%	Down 4%
Adjusted Operating Margin	5.5%	+150 basis points	+340 basis points

The overall financial impact of the 2025 fiscal year, ending September 30, 2025, showed a total Net Loss attributable to common shareholders of -$59.50 million, which was a significant improvement from the -$164 million loss in fiscal year 2024. This reflects the cost discipline applied across the core business as the divestiture process moved forward.

• Total FY 2025 Revenue (All Operations): $593.82 million.
• FY 2024 Total Revenue: $656.32 million.
• Cash, cash equivalents, restricted cash and marketable securities as of March 31, 2025: $540 million.
• FY 2025 Organic Revenue Growth Guidance (Reiterated): Range of 3% to 5% relative to fiscal 2024.

Finance: draft 13-week cash view by Friday.

Azenta, Inc. (AZTA) - Canvas Business Model: Revenue Streams

You're looking at how Azenta, Inc. (AZTA) converts its core life science services into actual dollars as of late 2025. It's all about the two main pillars now that they've streamlined the portfolio. Here's the quick math on where the money came from in fiscal year 2025 (FY25).

The overall picture for FY25 showed reported revenue of $594 million, marking a 4% increase year-over-year from continuing operations. This top-line performance resulted in a Non-GAAP Diluted EPS for the full fiscal year 2025 of $0.51.

The revenue streams are clearly segmented across their two primary business units. You can see the split below:

Revenue Stream Segment	FY25 Reported Revenue (in millions)	Year-over-Year Reported Growth	FY25 Non-GAAP Gross Margin
Sample Management Solutions (SMS)	$325 million	2%	49.3% (Q4'25 SMS Non-GAAP Gross Margin)
Multiomics	$269 million	6%	Not explicitly stated for full year, Q4'25 Non-GAAP Gross Margin was 46.7% (Total)

The Multiomics segment was the primary driver of the overall revenue increase for the full year, showing 6% growth, while SMS grew 2%.

Drilling down into the specifics of how these segments generate revenue, you see a mix of service contracts, product sales, and recurring consumables revenue. For the Multiomics business, the revenue streams are heavily weighted toward high-throughput genomic services:

• Multiomics services revenue: Includes gene sequencing, synthesis, and analysis.
• Next-Generation Sequencing (NGS) services showed impressive momentum, with volume rising 50% year-over-year in the fourth quarter.
• Multiomics delivered record revenue of $73 million in the fourth quarter of 2025.

The Sample Management Solutions revenue stream is more diverse, incorporating both capital equipment sales and ongoing service/consumable revenue. This is where you find the sales of automated storage systems and cryogenic freezers, alongside the critical recurring components.

Recurring revenue from Sample Repository Services (SRS) and consumables is a key component here, providing a more predictable base. Specifically, growth in Clinical Biostores, Consumables and Instruments, and Sample Storage were cited as drivers for the SMS segment in FY25. To be fair, revenue from Cryogenic Systems and Automated Stores was lower in the fourth quarter, but other core products offset that decline.

Here are the key revenue drivers within the SMS segment as reported for the fourth quarter:

• Recurring revenue from Sample Repository Services (SRS).
• Sales of consumables and instruments.
• Revenue from Clinical Biostores.
• Sales of automated storage systems and cryogenic freezers (though Cryogenic Systems revenue was lower in Q4'25).

Finance: draft 13-week cash view by Friday.